| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Lipofundin S does not have a specific pharmacological target in the traditional sense, as it is a nutritional emulsion rather than a drug. Its biological effects are related to its lipid content and its ability to modulate immune responses and mitochondrial function. It can inhibit the opening of mitochondrial permeability transition pores, protect the heart from ischemia-reperfusion injury, and regulate innate immune responses. It also favors proinflammatory cytokine production.
|
|---|---|
| ln Vitro |
Intralipid 10% (0-0.2 mg/mL) has little effect on cells, although it can shield cellular immune cells from paclitaxel's effects [1]. M0, M1, and M2 macrophages are stimulated to adopt a localized M1-like phenotype by intralipid 10% (0-0.2 mg/mL, 3 days) [1].
In vitro, Intralipid 10% (0-0.2 mg/mL) has little effect on cells but can shield cellular immune cells from the effects of paclitaxel. It stimulates M0, M1, and M2 macrophages to adopt a localized M1-like phenotype. These in vitro activities demonstrate its ability to modulate immune cell function and protect cells from chemotherapy-induced toxicity. |
| ln Vivo |
Observed in breast cancer tumor sections from Balb/c mice, Intralipid 10% did not influence phagocytosis and may increase macrophage localization to M1 phenotypic tissue [1]. Intralipid 10% boosts the action of paclitaxel in tumors, increases the distribution of paclitaxel in mice RES organs and enhances the inhibitory effect on growth [1]. Indifatin (5 mL/kg) accumulated and produced larger amounts of tumor cells than cyclosporine. It more effectively protects the SD stent from I/R degradation and lowers the dead area of identical stents by roughly 40% [2].
In vivo, Intralipid 10% did not influence phagocytosis but may increase macrophage localization to M1 phenotypic tissue in breast cancer tumor sections from Balb/c mice. It boosts the action of paclitaxel in tumors, increases the distribution of paclitaxel in mouse RES organs, and enhances the inhibitory effect on growth. It more effectively protects the heart from ischemia-reperfusion injury and lowers the dead area of identical stents by roughly 40%. |
| Enzyme Assay |
Lipofundin S does not have classical enzyme/receptor binding assays, as it is a lipid emulsion rather than a pharmacologically active compound. Its effects are studied in cellular and animal models. However, its ability to inhibit mitochondrial permeability transition pore opening can be assessed in cell-free systems using isolated mitochondria. These assays measure the compound's ability to prevent mitochondrial swelling and calcium-induced permeability transition.
|
| Cell Assay |
In vitro cellular assays for Lipofundin S assess its effects on immune cells and its ability to protect cells from toxicity. Macrophages (M0, M1, M2) are treated with Intralipid 10% (0-0.2 mg/mL, 3 days), and their phenotype is assessed. Its ability to protect cellular immune cells from paclitaxel's effects is also evaluated. These assays demonstrate the compound's immunomodulatory and cytoprotective effects.
|
| Animal Protocol |
In vivo animal studies for Lipofundin S have been conducted in Balb/c mice with breast cancer tumors. Intralipid 10% was administered, and its effects on macrophage localization, paclitaxel distribution, and tumor growth were assessed. In another study, its cardioprotective effects were evaluated in a stent model, where it protected the heart from ischemia-reperfusion injury and reduced the dead area.
|
| ADME/Pharmacokinetics |
Lipofundin S is a lipid emulsion that is administered intravenously as a nutritional supplement. Its pharmacokinetics are similar to those of other lipid emulsions, with the lipids being metabolized and cleared from the circulation. It is composed of soybean oil, glycerol, and soy phosphatides. The emulsion provides essential fatty acids and calories for patients requiring parenteral nutrition.
|
| Toxicity/Toxicokinetics |
Lipofundin S is considered a safe fat emulsion with low toxicity. It is used clinically as a nutritional supplement. However, as with any lipid emulsion, there is a risk of adverse effects such as hyperlipidemia, fat overload syndrome, and allergic reactions. Its safety profile has been well-established in clinical use. It is generally well-tolerated when used as directed.
|
| References | |
| Additional Infomation |
Lipofundin S is a lipid emulsion containing soybean oil, glycerol, and soy phosphatides, used as a nutritional supplement in parenteral nutrition. It is also known as Intralipid 10% or 20%. Beyond its nutritional use, it has been studied for its immunomodulatory effects, its ability to protect the heart from ischemia-reperfusion injury, and its potential to enhance the action of chemotherapeutic agents. It is a clinically approved product and is also used as a research tool.
|
| Molecular Formula |
C60H115NO10P
|
|---|---|
| Molecular Weight |
1041.52958130836
|
| Exact Mass |
1040.825
|
| CAS # |
68890-65-3
|
| Related CAS # |
Intralipid 20%;68890-65-3
|
| PubChem CID |
131750197
|
| Appearance |
White to off-white solid-liquid Mixture
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
55
|
| Heavy Atom Count |
72
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C/CCCCCCCC.CCCCC/C=C\C/C=C\CCCCCCCC(=O)O
|
| InChi Key |
ZACMUBKIFQNSDT-GAUHYDFOSA-O
|
| InChi Code |
InChI=1S/C42H82NO8P.C18H32O2/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-42(45)51-40(39-50-52(46,47)49-37-36-43(3,4)5)38-48-41(44)34-32-30-28-26-24-22-19-17-15-13-11-9-7-21-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h20-21,40H,6-19,22-39H2,1-5H36-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/p+1/b21-20+7-6-,10-9-
|
| Chemical Name |
(9Z,12Z)-octadeca-9,12-dienoic acid,
(E)-2-((hydroxy(2-(octadec-9-enoyloxy)-3-(palmitoyloxy)propoxy)phosphoryl)oxy)-N,N,N-trimethylethan-1-aminium
salt
|
| Synonyms |
Lipofundin S Lipofundin S 10 Intralipid 20 Intralipid
Medialipid Phospholipid - stabilized soybean oil Salvilipid
Travamulsion
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9601 mL | 4.8006 mL | 9.6013 mL | |
| 5 mM | 0.1920 mL | 0.9601 mL | 1.9203 mL | |
| 10 mM | 0.0960 mL | 0.4801 mL | 0.9601 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA